Cowen & Co. Reiterates $85.0000 Target On Exact Sciences (EXAS), Reiterates “Buy” Rating; Franklin Covey Co (FC) Has 0.88 Sentiment

June 19, 2018 - By Maria Brooks

Exact Sciences Corporation (NASDAQ:EXAS) Logo

Cowen & Co. have a $85.0000 price target on the stock. The price target indicates a potential upside of 23.60% from Exact Sciences (NASDAQ:EXAS)‘s last stock price. This rating was released in analysts note on Monday, 18 June.

Franklin Covey Co (FC) investors sentiment decreased to 0.88 in 2018 Q1. It’s down -0.34, from 1.22 in 2017Q4. The ratio is negative, as 29 institutional investors increased or started new holdings, while 33 cut down and sold their holdings in Franklin Covey Co. The institutional investors in our database now have: 6.32 million shares, down from 6.67 million shares in 2017Q4. Also, the number of institutional investors holding Franklin Covey Co in top ten holdings was flat from 2 to 2 for the same number . Sold All: 9 Reduced: 24 Increased: 13 New Position: 16.

Franklin Covey Co. provides training and consulting services in the areas of leadership, productivity, strategic execution, trust, sales force performance, customer loyalty, and communication effectiveness skills worldwide. The company has market cap of $401.64 million. The firm operates through four divisions: Direct Offices, Strategic Markets, Education Practice, and International Licensees. It currently has negative earnings. It also offers clients with training in management skills, relationship skills, and individual effectiveness, as well as personal-effectiveness literature and electronic educational solutions.

Analysts await Franklin Covey Co. (NYSE:FC) to report earnings on July, 5. They expect $-0.23 EPS, 0.00% or $0.00 from last year’s $-0.23 per share. After $-0.29 actual EPS reported by Franklin Covey Co. for the previous quarter, Wall Street now forecasts -20.69% EPS growth.

It closed at $28.9 lastly. It is down 39.09% since June 19, 2017 and is uptrending. It has outperformed by 26.52% the S&P500. Some Historical FC News: ; 04/04/2018 – Franklin Covey 2Q Loss/Shr 20c; 03/05/2018 – Franklin Covey Co. and Mango Media Inc. Release New Book, Building a Winning Culture in Government: A Blueprint for Delivering; 06/04/2018 – Franklin Covey Closes Below 50-Day Moving Average: Technicals; 20/04/2018 – DJ Franklin Covey Co, Inst Holders, 1Q 2018 (FC); 08/05/2018 – Franklin Covey Co. Named to Top 20 Sales Training Company List by Training Industry; 28/03/2018 – Franklin Covey Closes Above 50-Day Moving Average: Technicals; 14/05/2018 – Millar, Inc. Enhances its Commitment to Learning through FranklinCovey’s All Access Training Pass; 13/03/2018 – Franklin Covey Co. Named to Top 20 Leadership Training Company List by Traininglndustry.com for Seventh Year; 03/05/2018 – Franklin Covey Co. and Mango Media Inc. Release New Book, Building a Winning Culture in Government: A Blueprint for Delivering Success in the Public Sector; 30/04/2018 – FranklinCovey Recognized by HR.com with LEAD2018 Top Leadership Partner Award

Since January 1, 0001, it had 0 insider purchases, and 1 insider sale for $34,502 activity.

Osmium Partners Llc holds 10.28% of its portfolio in Franklin Covey Co. for 580,490 shares. Pembroke Management Ltd owns 836,051 shares or 2.38% of their US portfolio. Moreover, Punch & Associates Investment Management Inc. has 0.82% invested in the company for 346,816 shares. The California-based Rice Hall James & Associates Llc has invested 0.18% in the stock. Lapides Asset Management Llc, a Connecticut-based fund reported 20,100 shares.

Since January 2, 2018, it had 0 buys, and 21 insider sales for $25.11 million activity. LIDGARD GRAHAM PETER had sold 35,025 shares worth $1.50M on Monday, February 26. Shares for $87,474 were sold by COWARD D SCOTT. Conroy Kevin T had sold 125,402 shares worth $6.62 million on Friday, January 12. 3,098 Exact Sciences Corporation (NASDAQ:EXAS) shares with value of $126,925 were sold by Doyle James Edward. 8,448 shares were sold by Carey Thomas D., worth $335,630 on Tuesday, April 10. Shares for $243,068 were sold by ARORA MANEESH. 2,982 shares valued at $126,252 were sold by Elliott Jeffrey Thomas on Friday, February 23.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company has market cap of $8.38 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer. It currently has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

Investors sentiment increased to 1.15 in Q1 2018. Its up 0.27, from 0.88 in 2017Q4. It increased, as 43 investors sold Exact Sciences Corporation shares while 80 reduced holdings. 54 funds opened positions while 88 raised stakes. 101.92 million shares or 10.20% more from 92.48 million shares in 2017Q4 were reported. Price T Rowe Associate Md owns 50,143 shares or 0% of their US portfolio. Bluecrest stated it has 10,284 shares. Biondo Advsrs Ltd has invested 1.1% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS). Employees Retirement Association Of Colorado accumulated 0.01% or 20,958 shares. M&T Commercial Bank holds 0% or 16,309 shares in its portfolio. Sit Inv invested in 26,800 shares. Asset Mgmt One Co Limited stated it has 0% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS). Caprock Grp reported 6,360 shares. 21,500 are held by Atika Limited Liability Corporation. Hussman Strategic Advisors Incorporated owns 75,000 shares. Bankshares Of New York Mellon Corporation reported 1.56 million shares. Gilder Gagnon Howe Communications Ltd Limited Liability Company accumulated 2.00M shares. Jabre Capital Prtn Sa has 12,500 shares for 0.11% of their portfolio. Horseman Capital Mgmt owns 27,000 shares. Adams Diversified Equity Fund reported 11,000 shares.

More notable recent Exact Sciences Corporation (NASDAQ:EXAS) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares” on June 19, 2018, also Seekingalpha.com with their article: “Exact Sciences advancing biomarker panel for liver cancer” published on June 05, 2018, Streetinsider.com published: “Exact Sciences (EXAS) PT Raised to ‘Street High’ $85 at Cowen Following Colorguard Survey” on June 18, 2018. More interesting news about Exact Sciences Corporation (NASDAQ:EXAS) were released by: Seekingalpha.com and their article: “Exact Sciences upsizes and prices of 1.0% convertible senior notes due 2025” published on June 08, 2018 as well as Fool.com‘s news article titled: “20 Million More Potential Customers for Cologuard: Time to Buy Exact Sciences Stock?” with publication date: June 04, 2018.

Analysts await Exact Sciences Corporation (NASDAQ:EXAS) to report earnings on July, 24. They expect $-0.33 earnings per share, down 22.22% or $0.06 from last year’s $-0.27 per share. After $-0.33 actual earnings per share reported by Exact Sciences Corporation for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

The stock decreased 1.70% or $1.19 during the last trading session, reaching $68.77. About 976,299 shares traded. Exact Sciences Corporation (NASDAQ:EXAS) has risen 56.13% since June 19, 2017 and is uptrending. It has outperformed by 43.56% the S&P500. Some Historical EXAS News: 26/04/2018 – EXACT Sciences 1Q Rev $90.3M; 03/05/2018 – Vince Lombardi Cancer Foundation and Exact Sciences Team Up to Fight Colon Cancer; 17/04/2018 – Exact Sciences Closes Above 200-Day Moving Average: Technicals; 26/04/2018 – EXACT Sciences 1Q Loss $39.4M; 26/04/2018 – EXACT Sciences 1Q Loss/Shr 33c; 01/05/2018 – Exact Sciences Presenting at Bank of America Conference May 15; 19/03/2018 – Exact Sciences Closes Below 50-Day Moving Average: Technicals; 19/03/2018 – Harry Connick Jr. Is No Oprah Winfrey. Just Ask Exact Sciences; 02/05/2018 – Exact Sciences: A Big Opportunity? — Barrons.com; 30/05/2018 – American Cancer Society recommends earlier colorectal cancer screening

Among 18 analysts covering EXACT Sciences (NASDAQ:EXAS), 11 have Buy rating, 1 Sell and 6 Hold. Therefore 61% are positive. EXACT Sciences has $70 highest and $4 lowest target. $44.35’s average target is -35.51% below currents $68.77 stock price. EXACT Sciences had 78 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was downgraded by Benchmark on Friday, February 23 to “Hold”. On Tuesday, June 5 the stock rating was maintained by Robert W. Baird with “Outperform”. The rating was maintained by Bank of America on Tuesday, October 31 with “Buy”. The company was maintained on Thursday, January 18 by Craig Hallum. Canaccord Genuity maintained Exact Sciences Corporation (NASDAQ:EXAS) rating on Tuesday, October 3. Canaccord Genuity has “Buy” rating and $60.0 target. On Monday, July 17 the stock rating was maintained by BTIG Research with “Buy”. Canaccord Genuity maintained Exact Sciences Corporation (NASDAQ:EXAS) on Wednesday, June 6 with “Buy” rating. The stock has “Buy” rating by Roth Capital on Wednesday, July 26. The stock has “Buy” rating by Jefferies on Thursday, February 25. The stock has “Buy” rating by Jefferies on Wednesday, July 27.

Franklin Covey Co. (NYSE:FC) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>